Effect of FSW Parameters on The Microstructure and Mechanical Properties of T-joints between Dissimilar Al-Alloys

The main purpose of this research is to develop T-joints between the aluminum AA 2024-T4 and AA 7075-T6 using friction stir welding.  The effect of tool geometries, tool traveling speed, and rotational rate in the welded T-joints were investigated and discussed. Three different tools were used with different shoulder to pin ratios 3.28, 3.36, and 4.31. After optimization, the best tool dimension has used with the different rotational and welding speeds. Three tool traverse speeds of 50, 75, and 100 mm/min were used. Two rotation rates of 800 rpm and 1000 rpm were applied. After FSW, at a number of the above FSW parameters' combinations, macrostructure and microstructure analyses were done using optical microscopy. In order to have an insight into the mechanical properties, hardness measurements and tensile testing were carried out. Using small shoulder to pin ratio produced visually unacceptable T-joint. Opposite happened by using the tool with 4.31 of shoulder to pin ratio. Furthermore, the results showed sound T-welds with no obvious defects at high rotational rate of 1000 rpm with the two used traveling speeds. Asymmetric temperature distribution was observed between the two sides, advance side (AS) and retreating side (RS

Effects of ammonia toxicity on growth performance, cortisol, glucose and hematological response of Nile Tilapia (Oreochromis niloticus)

Ammonia is a production limiting factor in the aquaculture media affecting fish production. A study was designed to scrutinize effects of ammonia on growth performance, survival, cortisol and hematological parameters of Tilapia fish. The study examined effects of 96 h-incubation of male and female Tilapia with 3 mg ammonium chloride per a liter of water compared to control. The study has been carried out in the physiology laboratory of the department of animal and fish production, Alexandria University. Fourteen aquaria were used (6 control and 8 ammoniated). Each aquarium contained 6 fish (half the population males and the other have females). Duration of the control reared fish was 30 days, however the duration for ammoniated group was 4 days. In all stressed fish, there found decreases in final body weight, average daily gain and specific growth rate as compared to controls. Hematological parameters revealed increases (P0.05) in total leukocyte counts in both males and females exposed to stressors. There were significant decreases (P0.05) in red blood cell, hematocrit value and hemoglobin concentration in both males and females. There were non-significant differences (P0.10) in these parameters between males and females. Exposing both male and female tilapia to ammonia, resulted in increases (P0.05) in mean corpuscular volume (MCV). Mean corpuscular hemoglobin (MCH) didn’t change in male tilapia, while females expressed increased MCH values in the ammonia condition. Mean corpuscular hemoglobin concentration (MCHC) decreased (P0.05) under ammonia with no differences between males and females. Differential leukocyte count exhibited increases (P0.05) in neutrophils in ammonia-exposed males and females and decreases (P0.05) in eosinophils and monocytes in males, but not in females. However, lymphocytes decreased (P0.05) in both females and males exposed to ammonia. Cortisol level increased (P0.05) by about 2 folds in both sexes of fish exposed to ammonia (2.95 and 2.72 vs6.40 and 6.48 ng/ml in control males and females vs ammonia-exposed males and females).Rearing tilapia fish in media containing high level (3mg/l water) of ammonium chloride not only deteriorated growth rate but it also negatively affected the health wellbeing.

Molecular identification of adenoviruses associated with respiratory infection in Egypt from 2003 to 2010.

BACKGROUND: Human adenoviruses of species B, C, and E (HAdV-B, -C, -E) are frequent causative agents of acute respiratory infections worldwide. As part of a surveillance program aimed at identifying the etiology of influenza-like illness (ILI) in Egypt, we characterized 105 adenovirus isolates from clinical samples collected between 2003 and 2010. METHODS: Identification of the isolates as HAdV was accomplished by an immunofluorescence assay (IFA) and confirmed by a set of species and type specific polymerase chain reactions (PCR). RESULTS: Of the 105 isolates, 42% were identified as belonging to HAdV-B, 60% as HAdV-C, and 1% as HAdV-E. We identified a total of six co-infections by PCR, of which five were HAdV-B/HAdV-C co-infections, and one was a co-infection of two HAdV-C types: HAdV-5/HAdV-6. Molecular typing by PCR enabled the identification of eight genotypes of human adenoviruses; HAdV-3 (n = 22), HAdV-7 (n = 14), HAdV-11 (n = 8), HAdV-1 (n = 22), HAdV-2 (20), HAdV-5 (n = 15), HAdV-6 (n = 3) and HAdV-4 (n = 1). The most abundant species in the characterized collection of isolates was HAdV-C, which is concordant with existing data for worldwide epidemiology of HAdV respiratory infections. CONCLUSIONS: We identified three species, HAdV-B, -C and -E, among patients with ILI over the course of 7 years in Egypt, with at least eight diverse types circulating

Nutritive utilization of Moringa oleifera tree stalks treated with fungi and yeast to replace clover hay in growing lambs

Twenty four Barki lambs with an average body weight of 20.7 ± 0.17 kg were used in a complete randomized design to evaluate the effects of replacing clover (Trifolium alexandrinum L) hay as a traditional basal diet (C) with moringa tree stalks (MS) treated with fungi (Trichoderma reesei) (MF) and yeast (Saccharomyces cervisiae) (MY) under solid-state fermentation on nitrogen and water metabolism, rumen fermentation and economic efficiency of feeds. Lambs were divided into three groups each with eight lambs depending on their live weigh Concentrate feed mixture was similar for all groups and was offered at 2% of live weight with the basal roughage offered ad libitum. The results show that the rations had significant effects (P \0.05) on DM, crude protein and nitrogen free extract digestibility. Percentage total digestible nutrients was not affected (P \0.05) by the experimental rations and the values ranged between 0.62 and 0.64. The MY ration had the highest (P \0.05) digestible crude protein followed by C and MF. The roughage intake expressed as a percentage of total feed intake for MF and MY groups were higher by 4 and 2%, respectively compared to the control group. Average daily gains were 173, 139 and 146 g/head/day, for C, MF and MY groups, respectively. Average dressing percentages based on either fasting weight or empty weight were not affected by the experimental rations. There were no differences (P \0.05) among groups in N and water balance. Rumen NH -N concentrations for the MF and MY groups peaked (P \0.05) at 3 h post feeding whereas for the control it peaked at 6 h post feeding. Rumen TVFA’s concentrations for all treatments increased gradually from zero to 6 h post-feeding. MY diet recorded the highest (P \0.05) economical feed efficiency compared with MF and control diet. These results suggest that treatment of moringa stalks with S. cerevisiae for 21 days in a solid-state fermentation 3 system improved its nutritive value and is more suitable for practical feeding in sheep rations

Future and potential spending on health 2015-40 : development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries

Background The amount of resources, particularly prepaid resources, available for health can affect access to health care and health outcomes. Although health spending tends to increase with economic development, tremendous variation exists among health financing systems. Estimates of future spending can be beneficial for policy makers and planners, and can identify financing gaps. In this study, we estimate future gross domestic product (GDP), all-sector government spending, and health spending disaggregated by source, and we compare expected future spending to potential future spending. Methods We extracted GDP, government spending in 184 countries from 1980-2015, and health spend data from 1995-2014. We used a series of ensemble models to estimate future GDP, all-sector government spending, development assistance for health, and government, out-of-pocket, and prepaid private health spending through 2040. We used frontier analyses to identify patterns exhibited by the countries that dedicate the most funding to health, and used these frontiers to estimate potential health spending for each low-income or middle-income country. All estimates are inflation and purchasing power adjusted. Findings We estimated that global spending on health will increase from US$9.21 trillion in 2014 to$24.24 trillion (uncertainty interval [UI] 20.47-29.72) in 2040. We expect per capita health spending to increase fastest in upper-middle-income countries, at 5.3% (UI 4.1-6.8) per year. This growth is driven by continued growth in GDP, government spending, and government health spending. Lower-middle income countries are expected to grow at 4.2% (3.8-4.9). High-income countries are expected to grow at 2.1% (UI 1.8-2.4) and low-income countries are expected to grow at 1.8% (1.0-2.8). Despite this growth, health spending per capita in low-income countries is expected to remain low, at $154 (UI 133-181) per capita in 2030 and$195 (157-258) per capita in 2040. Increases in national health spending to reach the level of the countries who spend the most on health, relative to their level of economic development, would mean $321 (157-258) per capita was available for health in 2040 in low-income countries. Interpretation Health spending is associated with economic development but past trends and relationships suggest that spending will remain variable, and low in some low-resource settings. Policy change could lead to increased health spending, although for the poorest countries external support might remain essential.Peer reviewe

Future and potential spending on health 2015-40: Development assistance for health, and government, prepaid private, and out-of-pocket health spending in 184 countries

Background: The amount of resources, particularly prepaid resources, available for health can affect access to health care and health outcomes. Although health spending tends to increase with economic development, tremendous variation exists among health financing systems. Estimates of future spending can be beneficial for policy makers and planners, and can identify financing gaps. In this study, we estimate future gross domestic product (GDP), all-sector government spending, and health spending disaggregated by source, and we compare expected future spending to potential future spending. Methods: We extracted GDP, government spending in 184 countries from 1980-2015, and health spend data from 1995-2014. We used a series of ensemble models to estimate future GDP, all-sector government spending, development assistance for health, and government, out-of-pocket, and prepaid private health spending through 2040. We used frontier analyses to identify patterns exhibited by the countries that dedicate the most funding to health, and used these frontiers to estimate potential health spending for each low-income or middle-income country. All estimates are inflation and purchasing power adjusted. Findings: We estimated that global spending on health will increase from US$9.21 trillion in 2014 to$24.24 trillion (uncertainty interval [UI] 20.47-29.72) in 2040. We expect per capita health spending to increase fastest in upper-middle-income countries, at 5.3% (UI 4.1-6.8) per year. This growth is driven by continued growth in GDP, government spending, and government health spending. Lower-middle income countries are expected to grow at 4.2% (3.8-4.9). High-income countries are expected to grow at 2.1% (UI 1.8-2.4) and low-income countries are expected to grow at 1.8% (1.0-2.8). Despite this growth, health spending per capita in low-income countries is expected to remain low, at $154 (UI 133-181) per capita in 2030 and$195 (157-258) per capita in 2040. Increases in national health spending to reach the level of the countries who spend the most on health, relative to their level of economic development, would mean $321 (157-258) per capita was available for health in 2040 in low-income countries. Interpretation: Health spending is associated with economic development but past trends and relationships suggest that spending will remain variable, and low in some low-resource settings. Policy change could lead to increased health spending, although for the poorest countries external support might remain essential

Global, regional, and national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017

Background Understanding the patterns of HIV/AIDS epidemics is crucial to tracking and monitoring the progress of prevention and control efforts in countries. We provide a comprehensive assessment of the levels and trends of HIV/AIDS incidence, prevalence, mortality, and coverage of antiretroviral therapy (ART) for 1980–2017 and forecast these estimates to 2030 for 195 countries and territories. Methods We determined a modelling strategy for each country on the basis of the availability and quality of data. For countries and territories with data from population-based seroprevalence surveys or antenatal care clinics, we estimated prevalence and incidence using an open-source version of the Estimation and Projection Package—a natural history model originally developed by the UNAIDS Reference Group on Estimates, Modelling, and Projections. For countries with cause-specific vital registration data, we corrected data for garbage coding (ie, deaths coded to an intermediate, immediate, or poorly defined cause) and HIV misclassification. We developed a process of cohort incidence bias adjustment to use information on survival and deaths recorded in vital registration to back-calculate HIV incidence. For countries without any representative data on HIV, we produced incidence estimates by pulling information from observed bias in the geographical region. We used a re-coded version of the Spectrum model (a cohort component model that uses rates of disease progression and HIV mortality on and off ART) to produce age-sex-specific incidence, prevalence, and mortality, and treatment coverage results for all countries, and forecast these measures to 2030 using Spectrum with inputs that were extended on the basis of past trends in treatment scale-up and new infections. Findings Global HIV mortality peaked in 2006 with 1·95 million deaths (95% uncertainty interval 1·87–2·04) and has since decreased to 0·95 million deaths (0·91–1·01) in 2017. New cases of HIV globally peaked in 1999 (3·16 million, 2·79–3·67) and since then have gradually decreased to 1·94 million (1·63–2·29) in 2017. These trends, along with ART scale-up, have globally resulted in increased prevalence, with 36·8 million (34·8–39·2) people living with HIV in 2017. Prevalence of HIV was highest in southern sub-Saharan Africa in 2017, and countries in the region had ART coverage ranging from 65·7% in Lesotho to 85·7% in eSwatini. Our forecasts showed that 54 countries will meet the UNAIDS target of 81% ART coverage by 2020 and 12 countries are on track to meet 90% ART coverage by 2030. Forecasted results estimate that few countries will meet the UNAIDS 2020 and 2030 mortality and incidence targets. Interpretation Despite progress in reducing HIV-related mortality over the past decade, slow decreases in incidence, combined with the current context of stagnated funding for related interventions, mean that many countries are not on track to reach the 2020 and 2030 global targets for reduction in incidence and mortality. With a growing population of people living with HIV, it will continue to be a major threat to public health for years to come. The pace of progress needs to be hastened by continuing to expand access to ART and increasing investments in proven HIV prevention initiatives that can be scaled up to have population-level impact

Epigenetic modifiers induce bioactive phenolic metabolites in the marine-derived fungus penicillium brevicompactum

Fungi usually contain gene clusters that are silent or cryptic under normal laboratory culture conditions. These cryptic genes could be expressed for a wide variety of bioactive compounds. One of the recent approaches to induce production of such cryptic fungal metabolites is to use histone deacetylases (HDACs) inhibitors. In the present study, the cultures of the marine-derived fungus Penicillium brevicompactum treated with nicotinamide and sodium butyrate were found to produce a lot of phenolic compounds. Nicotinamide treatment resulted in the isolation and identification of nine compounds 1–9. Sodium butyrate also enhanced the productivity of anthranilic acid (10) and ergosterol peroxide (11). The antioxidant as well as the antiproliferative activities of each metabolite were determined. Syringic acid (4), sinapic acid (5), and acetosyringone (6) exhibited potent in vitro free radical scavenging, (IC50 20 to 30 µg/mL) and antiproliferative activities (IC50 1.14 to 1.71 µM) against HepG2 cancer cell line. Furthermore, a pharmacophore model of the active compounds was generated to build up a structure-activity relationship